Recent Finacing
Recent Raise
Pep2Tango Therapeutics develops unimolecular tetra-receptor peptide agonists targeting GLP‑1, GIP, amylin and calcitonin receptors for obesity, advancing CMC and IND-enabling studies toward a 2025 IND.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at Pep2Tango Therapeutics.
